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RESUMO 
Introdução: Em 2015, cerca de 415 milhões de pessoas a nível mundial eram diabéticas. Destas, 90-
95% eram tipo 2.    
A diabetes Mellitus tipo 2 é um estado metabólico crónico caracterizado por redução da 
síntese de insulina por parte das células beta pancreáticas, aumento da resistência periférica à 
insulina e redução das incretinas intestinais, culminando no aumento da glicose sérica.  
O tratamento da diabetes Mellitus tipo 2 pode englobar desde alterações no estilo de vida 
até cirurgia bariátrica. Esta última modalidade mostra evidências de ser a intervenção mais eficaz 
para o controlo da diabetes a curto/longo prazo. 
Os objetivos desta revisão são caracterizar as principais alterações, quer a nível estrutural 
quer hormonal, inerentes à cirurgia bariátrica e capazes de induzir melhoria no controlo dos níveis 
séricos de glicose a curto/longo prazo, comparar os resultados da cirurgia bariátrica com o 
tratamento conservativo preconizado para a diabetes Mellitus tipo 2 e validar as guidelines 
estabelecidas para o tratamento cirúrgico da diabetes. Além disso, avaliar as variáveis que alteram 
o prognóstico da cirurgia bariátrica e a eficácia dos scores existentes.  
Métodos: 74 artigos, desde janeiro de 2009 até janeiro de 2019, foram selecionados do PubMed e 
guidelines de diferentes organizações internacionais, tendo como base os critérios de 
inclusão/exclusão estabelecidos.  
Resultados: O aumento das hormonas intestinais, como o peptídeo semelhante ao glucagon 1, a 
redução de grelina e o bypass intestinal parecem ser as alterações associadas à cirurgia bariátrica 
que mais influenciam o controlo da diabetes pós-cirurgia. 
A cirurgia bariátrica, para doentes com IMC superior ou inferior a 35 kg/m2, é superior as 
medidas conservativas na resolução/controlo da diabetes Mellitus tipo 2. Cirurgias com 
características malabsortivas são mais eficazes, mas apresentam mais complicações a curto e longo 
prazo quando comparadas com cirurgias do tipo restritivas.  
Duração da diabetes e tratamento prévio com agentes hipoglicémicos são 
consistentemente referidos como fatores de remissão. O valor do peptídeo-C pré-cirurgia poderá 
condicionar o resultado da cirurgia bariátrica, mas mais estudos são necessários.  
Conclusões: A cirurgia bariátrica é uma modalidade de tratamento da diabetes mellitus tipo 2 com 
provas dadas em relação à sua eficácia, quer em termos do controlo da diabetes como da redução 
do peso. O mecanismo associado à sua eficácia parece ser uma combinação de fatores. 
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Um score com aplicabilidade no contexto clínico e com fatores demonstrados como sendo 
modificadores de prognóstico da cirurgia bariátrica deverá ser criado, no sentido de auxiliar na 
escolha da opção terapêutica mais eficaz para cada doente.  
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ABSTRACT 
Introduction: Diabetes Mellitus type 2 is a chronic metabolic condition characterized by peripheral 
insulin resistance and inadequate production by the pancreatic beta-cells, and reduction of incretin 
levels, culminating in a hyperglycemic state. 
Treatment for diabetes Mellitus type 2 ranges from lifestyle interventions to bariatric 
surgery. 
The aims of this review paper are to highlight the main hypothesis for DMT2 remission after 
bariatric surgery, the application of this type of surgery in DMT2 patients, regardless of BMI, and 
validate the current guidelines with study outcomes. Also, analyze the variables that alter surgery 
outcome on diabetes type 2 and the current remission scores.  
Methods: A literature review with 74 articles selected from PubMed and guidelines from different 
diabetes associations, based on exclusion/inclusion criteria was carried out. The articles were 
selected from 2009 to 2019. 
Results: The increase of gut hormones, decrease of ghrelin and intestinal bypass are the alterations 
created by some bariatric surgeries that most influence the glycemic control.  
Bariatric surgery, either in patients with Body Mass Index≥ or <35kg/m2, has proven to be 
more efficient than conservative measures in controlling diabetes Mellitus type 2. Surgeries with 
malabsorptive features are superior in achieving weight loss and DMT2 remission, but are 
associated with more post-surgery complications, compared to restrictive procedures.  
Duration of diabetes and use of hypoglycemic agents pre-surgery, excepted for metformin, 
are variables consistently associated with DMT2 remission. The current scores include variables 
with questionable influence on surgery prognosis, reducing their ability to predict outcome.  
Conclusion: Bariatric surgery appears to be an important element in the treatment of diabetes 
Mellitus type 2, showing better outcomes compared to conservative interventions, either on weight 
loss or glucose control. The main mechanism for diabetes remission after surgery seems to be a 
combination of factors. 
Defining a score with clinical applicability and factors consistently associated with 
remission, would improve selection of treatment for each individual and, therefore, diabetes 
control. 
Key words: Human; Bariatric surgery; diabetes Mellitus, Type 2; incretins; body mass index; blood 
glucose; 
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ABBREVIATIONS:  
National Institute for Health Care excellent: NICE;  
Diabetes Mellitus type 2: DMT2;  
Diabetes Mellitus: DM;  
Body mass index: BMI;  
Weight loss: WL;  
Roux-en-Y Gastric Bypass: RYGB;  
Fasting Glucose: FG;  
Glycated Hemoglobin: HbA1c;  
Low-density Lipoprotein: LDL;  
Triglycerides: TG;  
Systolic Blood Pressure: SBP;  
Sleeve gastrectomy: SG;  
Great curvature plication: GCP;  
Glucagon-like peptide-1: GLP-1;  
Peptide YY: PYY;  
Gastric inhibitory polypeptide: GIP;  
Cholecystokinin: CCK;  
Gastric bypass: GBy;  
Total body fat: TBF;  
laparoscopic adjustable gastric banding: LAGB;  
Gastric banding: GB;  
Biliopancreatic diversion: BPD;  
Intensive Medical Therapy: IMT;  
C- Reactive Protein: CRP;  
high sensitivity C-reactive protein: hs C-RP;  
Medical Treatment: MT;  
Homeostatic Model Assessment for Insulin resistance: HOMA-IR;  
Diabetes Surgery Summit: DSS; 
American Society for metabolic and Bariatric surgery: ASMBS; 
American Diabetes Association: ADA; 
International Diabetes Federation: IDF; 
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Randomized control-trial: RCT;  
High-density lipoprotein: HDL;  
Impaired glucose tolerance: IGT;  
Oral antidiabetic: ODA;  
Laparoscopic Sleeve Gastrectomy: LSG;  
Laparoscopic Sleeve Gastrectomy with Duodenal- Jejunal bypass: LSG-DJB;  
Vertical Banded Gastroplasty: VBG; 
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INTRODUCTION 
According to the National Institute for Health Care Excellent, NICE, diabetes Mellitus type 
2, DMT2, is a chronic metabolic state characterized by peripheral insulin resistance, inadequate 
pancreatic insulin production and reduction of incretin levels, culminating in a hyperglycemic 
environment1-3,. In table I are presented the diagnosis criteria for DMT2 established by the 
International Diabetes Federation, IDF.  
In 2015, 415 million individuals were living with DM, a much higher number compared to 
108 million in 19804. Of these 90-95% had DMT24,5. The number of people expected to have DM by 
2030 is presumed to reach 438 million6 and 592 million by 20357, making this disease the biggest 
healthcare threat of the century6. In 2015, 13.3% of Portuguese, between 20-79 years, were 
diabetic and this disease is believed to be responsible for 3-4% of deaths in Portugal every year, but 
the mortality rate associated to DM is showing tendency to decrease8.  
DMT2 can have a negative impact on multiple organs and systems9. Complications can be 
divided into microvascular, affecting mainly the retina (proliferative or non-proliferative 
retinopathy), the kidneys (diabetic nephropathy) and the nerves (central, autonomous, peripheral 
and sensorimotor), and macrovascular (ischemic heart, cerebrovascular and peripheral vascular 
disease)9,10. Interventions aiming glucose control help prevent and minimize organ-damage 
associated to diabetes Mellitus, DM10. 
It’s believed that obesity increases the risk of DMT2 by 80-85%1,11,12. In Portugal, 55.4% of 
diabetics are obese8. Almost every morbidly obese adult, define as Body mass index (BMI) ≥40 
Kg/m2 13, has some level of impaired glucose tolerance, IGT, and 36% of these will evolve to DMT2 
in 10 years14. Obesity is known to create a chronic state of low-grade inflammation and that can be 
a possible mechanism behind insulin resistance in people with excess weight. Also, increase of fatty 
acids and supression of adiponectin ara associated with obesity11,15. 
The standard treatment for DMT2 starts with lifestyle interventions, mainly appropriate 
diet and exercise, and then, if this isn’t effective, moves on to oral/injectable therapy. The first drug 
introduced is usually metformin, with addition of a second oral medication if target glycated 
hemoglobin, HbA1c, is not achieved with the first and so on16.  
Weight Loss, WL, is a crucial element in the management of DMT21. Decrease, of at least 
5% of the initial weight, can improve complications associated with DMT217. Conservative 
measures, aiming to control DMT2 and weight, usually produce moderate WL, 5-10% of baseline 
body weight, don’t stop pancreatic β-cell decline and, at short-term, the patients tend to regain the 
weight lost2,3,11.  
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Bariatric surgery was first designed to help on WL, but the first reports suggesting 
improvement of obesity comorbidities were presented in the ‘70s18. Nowadays, the superiority of 
bariatric surgery compared to conservative measures to treat not just obesity, but also associated 
metabolic disorders, such as DMT2, is undisputable4 and these results can last long periods of 
time19. Roux-en-Y gastric bypass, RYGB, for example, is capable of reducing BMI, HbA1c, fasting 
glucose, FG, insulin resistance, triglycerides, TG, low-density lipoprotein, LDL, and systolic blood 
pressure, SBP, without major complications in most of the patients 20,21. 
In the past, WL was the main alteration associating DMT2 remission to bariatric surgery, 
but modification on glucose levels usually happens within days after surgery, before significant WL. 
Mechanisms weight-loss-independent, as gut hormones modification, intestinal bypass and 
decrease of pro-inflammatory state have been reported, and may probably explain the positive 
impact of some bariatric surgeries in the course of DMT23,22.  
OBJETIVES 
The objectives of this review paper are to highlight the main hypothesis for DMT2 remission 
after bariatric surgery, focusing primarily in the gut hormones modifications, the application of this 
type of surgery in DMT2 patients, regardless of BMI, and validate the current guidelines with study 
outcomes. Also, because nowadays the main criteria for bariatric surgery is BMI, confront the 
information of different studies and verify if BMI is a predictor of remission and analyze other 
possible variables.  
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METHODS 
 
Search strategy 
The research platforms used for this review were PubMed and the IDF, NICE, American 
Society for metabolic and Bariatric surgery, ASMBS, and American Diabetes Association, ADA 
websites. The search went from December 2018 and January 2019 and was based on the following 
key word combination: “bariatric surgery” and “gastrectomy”, “diabetes mellitus type 2”, “body 
mass index”, “treatment outcome”; “Bariatric surgery” and “gastrectomy”, “diabetes mellitus type 
2”, “remission factors”; “Bariatric surgery” and “gastrectomy”, “diabetes mellitus type 2”, “ghrelin” 
OR “GLP-1”.  
Inclusion Criterion 
For this review, inclusion criteria were the following: review articles and meta-analysis, 
guidelines and case control studies written in English or Portuguese dated from 2009 to 2019. The 
articles selected focus on outcome of DMT2 after Bariatric surgery, independently of BMI, 
mechanisms associated with DMT2 and remission factors. Guidelines chosen were based on the 
relevance of each institution on DM field. 
 Exclusion Criteria 
In this review, articles in languages other than English or Portuguese, were excluded. Also, 
articles focusing only on the following theme weren’t selected: outcome or mechanism of bariatric 
surgery on obesity or other comorbidities different to DMT2, treatment of DM type 1, studies with 
patients under 18 years-old and studies comparing, especially when the inclusion criteria was 
BMI>35, just different types of bariatric surgery, without including a comparative group with 
conservative intervention. 
Article Selection 
Out of the first selection, based on mesh words, selection of type of articles and established 
data range (from January 2009 to January 2019), 52 articles were selected. Based on abstract, main 
focus and inclusion/exclusion criteria define previously, 38 articles were included in this review. 7 
articles/guidelines from different DMT2 associations and ADA website were added. 
From the selected articles, by consulting each bibliographic references, where the data 
range was still taken into consideration, 29 were selected and the final number of articles for this 
review are 74. The schematic article selection is represented on Figure 1. In the articles focusing on 
outcome, the main variables analyzed (when available) were: WL, remission definition and rate 
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(partial/total), HbA1c and/or FG (parameters of glycemic control), number of medication 
required/patient.  
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RESULTS 
The effects of Bariatric surgery on gut Hormones 
 
The first theories reporting the mechanisms behind DMT2 remission after bariatric surgery 
emphasized in the hypocaloric state inherent to food restriction, which would lead to WL11,16,23,24. 
The main theory, the starvation-followed-by-WL24,25, is supported by the fact that all types of 
bariatric surgery are able to improve glucose metabolism within days, mainly by increase of hepatic 
insulin sensitivity, which is associated with reduce food intake. Peripheral insulin sensitivity also 
improves, but only after decrease of ≥15% of baseline body weight11. However, this theory lacks on 
explaining why DMT2 remission varies depending on the type of bariatric surgery, even though 
some produce similar WL11,24.  
In a prospective non-blinded study with 45 patients divided equally in 3 groups, they’re 
submitted to either RYGB, sleeve gastrectomy, SG, or great Curve Plication, GCP. One month after 
each surgery, WL was similar between interventions, but glucose levels decrease was more 
accentuated after RYGB26. Fasting glucagon-like peptide-1, GLP-1, levels were similar between 
surgeries at baseline, 1 and 12 months of follow-up, but after food intake, GLP-1 rose more with 
RYGB during the 12-months follow-up. Fullness GLP-1 increased similarly in the surgeries with 
restrictive features. One month after each surgery, fasting peptide YY, PYY, and ghrelin levels were 
identical between the groups of participants, but were more elevated with RYGB at 12 months26.  
In a study with 52 patients, all female, 3 surgical groups were formed: Gastric Banding (16 
patients), GB, biliopancreatic diversion, BPD, (16) and Gastric plication, GP, (20) the last one a 
procedure with malabsorptive and restrictive features. They’re placed in each surgery group based 
on individual contraindications for the other procedures. Age and duration of DMT2 were equal 
between groups. The patients were evaluated in three moments during follow-up: 2 days, 1 and 6 
months after surgery. Improvement of anthropometric parameters, fasting blood glucose, FBG, and 
DMT2 happened after all surgeries, but was more pronounce in the BPD group. FBG alteration was 
primarily seen in the first month after BPD. GIP levels decreased mainly in the first month after BPD, 
and were steady at 6 months, contrarily to the levels after GP, which increased, and GB, which 
produced no alteration on GIP levels. GLP-1 levels started to increase 2 days after BPD and kept 
rising during the first month, with stabilization at 6 months of follow-up, opposite to levels after 
GB, which started to increase only after 1 month, and GP, which decreased during this period27. 
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A prospective trial compared the outcome of 60 patients, all divided equally in 3 groups of 
intervention, during two years: RYGB+Intensive medical treatment, IMT, SG+IMT or IMT. Baseline 
GLP-1 levels, pmol/L, 60 minutes after food stimulation, increased from 2.0 to 12.5 in the RYGB+IMT 
group, 2.4 to 7.3 in the SG+IMT and in the IMT patients no change was seen during follow-up. 2 GIP 
levels, pmol/L, also after food intake, reduced during follow-up in the RYGB+IMT group (30.7 to 
13.5), and levels differed significantly from the other two groups 2. Levels of high sensitivity C- 
reactive protein, hs C-RP, dropped similarly in the two surgical groups and no change was reported 
in the IMT patients2  
In a 2-years follow-up study with BMI<35 kg/m2 as inclusion criteria, complete remission 
rates were 50% with gastric bypass, GBy, and 5.5% with SG. This rates were achieved with similar 
WL, but more accentuated waist reduction in the GBy patients. Insulin secretion was normalized 
with both surgeries during the follow-up, but insulin resistance, calculated using the Homeostatic 
model assessment for insulin resistance, HOMA-IR (glucose x insulin/22.5), decreased more in the 
GBy group, even though both surgeries induced reduction25. In terms of gut hormones, both 
surgeries had the same effect in PYY and GLP-1 levels 30 and 60 minutes after food ingestion, but 
SG patients had a decrease on PYY at minute 90. Fasting GIP levels were similar between surgeries, 
but SG patients had a significant increase 30 and 60 minutes after food stimulation. Fasting acyl 
ghrelin, AG, increased more after GBy in a 2 years period and experienced bigger reductions 30 and 
60 minutes post-prandial also with GBy25.  
In the Malin et al. study (characteristics of the study in table number II), fasting and after 
food stimulation GLP-1, GIP and acyl ghrelin, AG, levels were similar between patients in remission 
and no-remission at 12 months, but GLP-1 levels after meal stimulation at 24 months were 
significantly superior in the “no-remission” group compared to “remission” patients. Hs-CRP, 
decreased more in the remission group at 12 and 24 months and this decline was associated with 
decrease of FG and increase of glucose-dependent insulin release during-follow-up. Also, at 2 years, 
was linked to normal β-cell function. Adiponectin levels had bigger elevations in the “remission” 
group and, at 12 months, correlated with reduction in android body fat, decrease hepatic insulin 
resistance, improvement of glucose-stimulated insulin secretion, and β-cell normal function28.  
A clinical trial with 24 patients, all with BMI over 40 kg/m2, involved two types of 
procedures: RYGB or RYGB plus gastric fundus removal, RYGB- GF. Baseline characteristics and 
hormone levels were all similar. The patients were evaluated at 3 points: 3, 6 and 12 months after 
each procedure. BMI levels decreased similarly in the two groups and glucose levels mainly in the 
RYGB- GF at 12 months follow-up. Fasting ghrelin levels decreased 3 months after surgery in the 
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RYGB group, but increase beyond baseline until the end of the follow-up, contrarily to RYGB-GF that 
showed decrease during the entire follow-up. Post-prandial ghrelin levels were partly suppressed 
in both surgical groups. Fasting GLP-1 levels didn’t change at any point of the study in both groups, 
opposite to post-prandial levels, which increase in both groups, primarily in the RYGB- GF group. 
Fasting and post-prandial PYY levels increased with the two interventions, but mainly in the RYGB-
FG group, and earlier, especially post-prandial levels29. 
Remission Predictors 
37 patients were selected for a retrospective trial aiming to compare RYGB and SG. 40% in 
the RYGB and 27% in the SG group achieved DMT2 remission. 12 and 24 months after each 
intervention, two groups were formed: patients in “remission” and “no-remission”. At baseline, 
“non-remission” patients were older, used more ODA pre-surgery, had bigger DMT2 duration, 
lower fasting C-Peptide, percentage of TBF and insulin sensitivity. Higher baseline adiponectin and 
less use of medication were correlated with normal glycemic status 12 and 24 months after each 
surgery. Increase of baseline adiponectin levels 12 months after surgeries was associated with 
decrease android body fat, diminished hepatic insulin resistance, higher β-cell function and glucose-
dependent insulin secretion28. 
Panunzi et al. analyzed different interventions in 727 patients during a 2-years period and 
defined shorter duration of diabetes, younger age, no use of hypoglycemic medication and lower 
levels of FG as general predictors of DMT2 remission 2 years after bariatric surgery. Baseline 
characteristics associated with glycemia change were pre-treatment glycemia levels, HbA1c and 
HOMA-IR. For HbA1c variation during the follow-up the baseline factors were triglycerides, waist 
circumference and glycemia levels. BMI was not considered a factor for remission but, analyzing 
BMI by intervals, BMI>40 kg/m2 had a risk of remission of 2.9 compared to BMI≤35 kg/m2 and no 
different was seem between BMI≤35 kg/m2 and BMI 35-40 kg/m2. Predictors of remission changed 
depending on the type of surgery. In purely restrictive procedures, diabetes duration, FG levels and 
need for medical treatment were inversely correlated with remission. In procedures with 
malabsortive features FG was the only predictor30. 
A retrospective study composed by 254 severely obese patients (47.6±9.1 kg/m2) after 
RYGB operation, had a follow-up period of 3 years minimum. During the study, 81.9% of patients 
achieved either partial (69.7%) or complete remission (12.2%), define by ADA31 (table III). Age <45, 
DMT2 duration≤5 years and HbA1<7.0% pre-operative were all define as good remission factors for 
complete remission. Patients with DMT2 duration ≤5 years or 6-10 years and HbA1c<7% or <8.5-
10% were more likely to achieve partial remission than patients with DMT2 duration>10 years and 
HbA1c>10%, respectively. 12% of patients that achieved either complete/partial remission, 
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relapsed during the duration of follow-up, in average 3 years after remission. The use of any 
hypoglycemic medication, excepted for metformin, was associated with probability of relapse32. 
Ramos-Leví et al. developed a 5-years study focusing on relapse and glucose variability, GV, 
in patients in remission 18-24 months after Bariatric surgery. The authors chose 24 patients in 
remission, 12 submitted previously to RYGB and 12 to single anastomosis duodeno-ileal bypass with 
SG, SADI-S. At 5 years, all the patients of the SADI-S group and 6 patients of RYGB were in remission. 
GV at 18-24 months was demonstrated to be higher in the patients submitted to RYGB that were 
in remission compared to SADI-S patients.  Mean glucose levels (remission: 88 mg/dL compared to 
no-remission: 95.33 mg/dL), amplitude of variation from mean blood glucose, maximum blood 
glucose levels registered and percentage of time spent with glucose level>140 mg/dl were 
parameters higher in patients that weren’t in remission at 5 years follow-up compared to remission. 
GV was showed in this study to be a good method to evaluate long term remission33. 
In a retrospective study conducted in Korea by Kim et al. analyzed the impact of types of 
reconstructions and stomach size in 403 patients with gastric cancer submitted to gastrectomy 
during an average period of follow up of 33 months and BMI 24.7 ±3.0 kg/m2. Three types of 
procedures were analyzed: subtotal gastrectomy followed by gastroduodenostomy, Billroth I, 
subtotal gastrectomy followed by gastrojejunostomy, Billroth II, and total gastrectomy followed 
esophagojejunostomy, RYGB. Comparing outcomes, the groups of total gastrectomy and duodenal 
bypass had better results compared to the opposites groups, subtotal gastrectomy and without 
duodenal bypass, respectively, and these variables were statistically significant associated to 
resolution of DMT2. Analyzing remission factors in each type of surgery, reduction of baseline BMI 
and follow-up duration were always associated with remission34. 
In a study aiming to determine predictors of remission and relapse at 5 years after RYGB, 
175 patients were evaluated. Of those, 61% achieved either total or partial remission at 1 year, 54% 
were in remission 5 years after surgery, 25% at remission in the first year relapsed and 31% never 
achieved remission during the study. The study formed three groups: the one at 5-years remission, 
5-R, the ones that relapsed at 5 years, 5-Relapse, and the group that never achieved remission, 5-
RN. The 5-R, at baseline, had less duration of diabetes, fewer ODA, better glucose control and 
insulin use, were expect to be woman and with more weight, but less abdominal fat. Analyzing body 
composition, patients at 5-R lost more weight and abdominal fat at 6 and 12 months compared to 
the 5-NR group and the amount of weight lost was a factor statistically significant when comparing 
the 5-R and the 5-Relapse. Importantly, even though during the follow-up all groups experience 
weight regain, the 5-Relapse group experienced a bigger gain, including fat mass. Levels at 1 year 
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follow-up of HbA1c and FG were associated with 5-NR and patients that had partial remission or no 
remission at 1 year were less likely to achieve remission at 5 years 35. 
Outcome 
In a study comparing lifestyle and surgical treatment (type of intervention and number of 
participants – table II) during a two years period, the remission rate was 63.7% in the surgical group 
and 15% in the medical group. At baseline, the lifestyle group had better anthropometric 
parameters (BMI, weight and waist circumference) and older mean participants than the surgical 
group. 2 years later, percentage of WL (-22.4±10.8 versus -2.5±6.5, %), reduction of waist 
circumference (-16.0±9.1 compared to -1.3±11.9, %) and HbA1c (table II) levels were all parameters 
statistically improved by surgery compared to lifestyle interventions.30 In other randomized study 
comparing RYGB and intensive lifestyle intervention, 19 patients in each group were evaluated 
during a period of 3 years. Baseline characteristics were similar. In the year 1, 11 patients in the 
RYGB group and 3 of the ILI achieved glucose parameters goals, decreasing to 8 at year 3 with RYGB 
and 0 in the ILI. At the end of follow-up, 58% of RYGB patients achieved HbA1c<7%, contrasting 
with 11% in the ILI. 36 HbA1c decreased primarily in the first year of follow-up in the RYGB group, 
with stabilization of this parameter during the following 2 years. FPG, WL, BMI, TBF, waist 
circumference and quality of life were all parameters improved mainly in the RYGB group36. 
In the Kashyap et al. trial, 24 months after starting each intervention, all groups dropped 
their mean HbA1c, particularly in the RYGB+IMT group (table II). Relapse from 12 to 24 months of 
follow-up occurred in all groups, but the most pronounce was with SG+IMT (table IV). Mean FG, 
weight and total body fat, TBF, were all parameters improved primarily in the surgical groups. TBF 
increased during follow-up in the IMT group and abdominal fat decreased mainly with RYGB+IMT 
and this was statistically significant compared to the other two interventions. The mean baseline 
percentage of patients using insulin was 46.3% and at 24 months, almost all patients in the surgical 
groups dropped out insulin, contrarily to the IMT group, which increased the percentage of users 
for 59%2. 
In a 5-years study with 60 patients with BMI≥35 kg/m2, 3 groups, divided in 1:1:1 and 
randomized, were formed and submitted to different therapies: RYGB, BPD or medical treatment, 
MT. At baseline, all parameters were equal, but 82% were women. 5 years after each intervention, 
50% of the surgical group achieved partial remission, mostly patients in the BPD group, and none 
achieved total remission (table IV). In the MT group no patient achieved partial/total remission. 
Independently of remission status, 42% of RYGB and 68% of BPD patients reached HbA1c≤6.5% 
during the 5 years follow-up without medical treatment, compared to 27% in the MT that achieved 
this target HbA1c, but with hypoglycemic medication. FG levels decreased in all groups, but 
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primarily and statistically significant in the BPD group, and the same happen with HbA1c, insulin 
resistance, calculated by HOMA-IR, WL and waist circumference. 47% of the surgical group at 
baseline needed insulin±other hypoglycemic medication, but at the end of the follow-up period no 
insulin was prescribed for these patients and 87% of the surgical group didn’t required 
hypoglycemic medication during the course of the study. Contrariwise, in the MT group the use of 
oral antidiabetic, ODA, and insulin increased during the follow-up37. 
In a randomized control trial, RCT, with 61 participants, three interventions were evaluated: 
RYGB, laparoscopic adjustable GB, LAGB and intensive lifestyle intervention, ILI. At year 2 of follow-
up, the three interventions stopped and all patients started low ILI. Total and partial remission at 3 
years were only obtain in the surgical groups and mainly with RYGB patients (table IV). Analyzing 
the glycemic parameters, the RYGB group was the one that suffered bigger declines from baseline 
in HbA1c levels and FPG, -66 mg/dL (p<0.05 compared to the other two interventions), followed by 
LAGB (table II). The percentage of WL, waist circumference and TBF was statistically greater in the 
RYGB group versus the other two interventions. The use of antidiabetic medication declined in the 
surgical groups, with 72% and 45% of the RYGB and LAGB patients, respectively, not requiring any 
hypoglycemic agent after 3 years of intervention. All patients in the ILI group required hypoglycemic 
drugs during follow-up38.  
In a prospective non-randomized study comparing the effect of RYGB and 2 medical 
interventions (GLP-1 analog or SGLTA inhibitor), 90 patients with class I obesity, equally divided in 
3 groups of intervention, were followed during 1 year. The patients were allocated in each 
intervention group based on their preference after learning about them. Baseline characteristics 
were similar between groups, excepted for mean BMI, which was superior in the RYGB patients. In 
all groups, the patients maintain the therapy they were on before starting this trial. Clinically 
important weight lost, define as WL superior to 5% from baseline during 6-12 months of 
intervention, was observed in all patients in the RYGB group, 56.7% of the GLP-1 analog 
intervention group and in no patients in the SGLTA inhibitor group. HbA1c end–point was achieved 
in all patients submitted to RYGB and, even though the other two groups had reduction of HbA1c, 
no patient in the medical groups reached the ideal HbA1c (table IV). The number of hypoglycemic 
medication/patient reduced with RYGB and GLP-1 analog, but no significant decrease was watched 
in the third group39. 
In a prospective RCT with initial 1808 participants, Cummings et al. choose 43 patients with 
BMI 30-45 kg/m2 and mildly uncontrolled DMT2 to be randomized and treated with one of two 
treatment options: RYGB or ILI (table II), for 1 year. At baseline, all variables were similar, except 
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duration of DMT2, which was statistically superior in the RYGB group. During the follow-up, 11 of 
the initial patients dropped from the study, leaving the RYGB group with 15 participants and 17 in 
the ILI. The authors documented statistically better results in the RYGB group on diabetes remission 
and HbA1c levels (table II and IV) and ability to maintain these levels during follow-up. At baseline, 
60% of RYGB patients were insulin users compared to 47% of ILI patients. After 1 year, the 
percentage of ILI patients was kept equal, opposite to the percentage in the RYGB group, which 
dropped to 21%, and all patients in surgical group dropped at least ≥1 hypoglycemic medication 
(average ODA/person at 1 year:  0.5±0.2 versus 1.2±0.2 in the ILI). Insulin resistance, calculated 
using HOMA-IR, and anthropometric parameters declined in both group, but more with RYGB40. 
A RCT comparing bariatric surgery, RYGB or SG, to IMT was designed to have 3 phases of 
follow-up: at 1, 3 and 5 years after each intervention. 150 patients with BMI 27-43 kg/m2 and badly 
controlled DMT2 (table II) were selected to initiate this study, but only 89% completed it. Baseline 
characteristics were similar between the three groups, except for the percentage of women, 
superior in the SG group. At 12 months, 12% of the medical group, 40% of the RYGB and 37% of the 
SG achieved the main end-point, HbA1c<6 %, with or without hypoglycemic agents. At 3 years, 5%, 
38% and 24% achieved the end-point, respectively, and lastly, at 5 years, the percentages remain 
the same excepted in the RYGB group, which decrease to 29%. Remission rates during follow-up 
were superior in the surgical group and relapse at 3 years was superior in the medical group (table 
IV). FG and HbA1c  (table II) decreased significantly in the surgical group compared to the IMT group, 
especially in the first three months, and the levels remain stable during the study. Anthropometric 
parameters improved in bigger extend in the surgical group during the study, especially with RYGB. 
The percentage of excess body weight decreased much more in the surgical group after 1 year of 
intervention, 88% in the RYGB and 81% in the SG, compared to the surgical group, 13%. Excess 
weight regain at 3 years, define as increase of >5% of baseline weight, happen only in IMT patients 
(7 out of 43). Three years after each intervention, 69% of the RYGB and 43% on the SG group didn’t 
need any hypoglycemic agent and at 5 years 45% and 40%, correspondingly, were still without any 
medication. Percentage of insulin users decreased in all groups during the 5 years follow-up, but 
was only statistically significant in the surgical group. The number of ODA/patient in the IMT group 
increased during follow-up41,42,43. 
Guidelines 
In 2007 the first Diabetes Surgery Summit, DSS-I, was held in Rome with the aim of 
reviewing all the clinical data available about application of bariatric surgery on DMT2 and expand 
the research and use of this treatment option. In 2015, in the second DSS, with the help of 48 
members from different countries, organizations and medical fields, it’s developed a global clinical 
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algorithm, including medical and surgery treatment, for the management of DMT24,44 The algorithm 
designed is showed on table V in the complementary section. The experts also defined 
contraindications for the use of surgery on the treatment of DMT2: DM type 1, unless the procedure 
is indicated for other reason other than diabetes, current use of drugs or alcohol, diminished 
comprehension of risks/benefits/outcome, uncontrolled psychiatric disease and/or low adherence 
to nutritional supplementation and long-term follow-up necessary after surgery4,44.  
The latest guidelines by IDF4, NICE5, ADA45, and ASMBS46 follow the same principles defined 
in the DSS-II meeting. Bariatric surgery is recommended in patients with BMI≥35 kg/m2 and DMT2 
after ineffective conservative measures and can be also suggested in patients with BMI between 
30-35 kg/m2 with uncontrolled glucose levels after intensive conservative measures, including use 
of injectable hypoglycemic agents. With BMI≥40 kg/m2, surgery should be suggest, regardless of 
glucose control47. Interestingly, all cut-offs must be down 2.5kg/m2 when apply to Asian patients, 
because patients of this nationality are exposed to more DMT2 risk with lower BMI2,48,49. In this 
population, the cause of DMT2 seems to be beta-cell dysfunction with late and diminished insulin 
secretion7. 
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DISCUSSION 
Mechanism of Bariatric surgery on DMT2 remission 
 
Currently, the main hypothesis explaining the effect of RYGB in DMT2 pathophysiology are: 
ghrelin, upper or lower intestinal hypothesis.  
The principle of the first theory is that ghrelin release is altered after RYGB due to lack of 
food contact stimulation. Ghrelin, a prodiabetic and orexigenic hormone24,26, is produced mainly in 
the gastric fundus by the A cells, but it can also be secreted in the duodenum15. This hormone 
increases food intake and adipogenesis and is probably responsible for inhibit insulin secretion3,15. 
The circulating levels vary with BMI and weight oscillations11,14,24. In obese patients, total ghrelin 
tends to be diminished11,14. In diet-induce WL the levels rises 14,24, but after bariatic surgery, mainly 
the ones where exclusion of gastric fundus is included, is expected a reduction of this hormone24,26.  
AG, on the contrary, is increased in obese patients, during periods of fasting and fullness. This 
hormone seems to have a more powerful role in the appetite regulation than total ghrelin, mainly 
because of its action on the hypothalamic food initiation center.  In a trial with 60 patients, analyzing 
just the surgical groups included, AG (fasting and post-prandial) and total ghrelin increased 
primarily with RYGB and SG, respectively, but the patients submitted to RYGB had bigger DMT2 
remission rates with weight loss similar to SG patients15. Few studies reported that ghrelin levels 
had a tendency to return to baseline values within months11,14,15. This alteration seems to work 
negatively for WL after RYGB26.   
Chronaiou et al. showed that, by removing the gastric fundus, ghrelin and other gut 
hormones (in this case, post-prandial GLP-1 and PYY levels) vary29. The alterations of gut hormones 
postoperative seen in this study and others demonstrate that ghrelin isn’t the only alteration, 
caused by bariatric surgery, that positively impacts DMT2. Surgeries that involve intestinal bypass 
are consistently associated with better outcome, with or without stomach manipulation, so other 
pathways must also be modified. Therefore, ghrelin hypothesis doesn’t explain entirely the 
mechanism behind bariatric surgery, even though decrease of ghrelin levels plays some part. 
RYGB is known to be superior to SG in inducing DMT2 remission and the upper or the lower 
intestinal theories can be possible explanations22. The upper intestinal (or foregut) hypothesis 
states that, if the nutrient doesn’t contact with the duodenum and jejunum, then it can improve 
diabetes status11,22,24,50. Two possible explanations for this are the existence of a portal vein sensor 
pathway and/or intestinal gluconeogenesis. Analyzing GB and RYGB, the differences in DMT2 
remission between the two types of surgeries can be eliminated if denervation of portal vein is 
induced11,26. According to animal models, when bypassing the proximal intestine, intestinal 
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gluconeogenesis is increased, causing rise on glucose concentration in the portal vein, which is not 
seen after GB, a procedure without intestinal bypass11.  
The creation of big intestinal bypasses, without manipulation of the stomach size24,51or with 
gastric pouches bigger than the ones created in the standard RYGB26,37, resulted in improvement of 
glucose levels, superior to control groups. This leads to conclude that bypassing the intestinal plays 
an important role on the positive effect of bariatric surgery on DMT2, but other factors can be 
involved. 
The lower theory, or hindgut, is based on the gut hormones alterations created with the 
intestinal bypass. By altering the intestinal architecture, it speeds up the delivery of nutrients and 
increases the release of gut hormones, for example GLP-122,50. This hormone is an incretin released 
from the L cells in the ileum3. Incretins are promptly released during food intake and have a half-
life of minutes3. They work by stimulating glucose-dependent insulin secretion and their effect is 
more visible after oral food intake than IV administration3,11.  GIP is also an incretin, but in its case, 
released from duodenum. After surgery, the increase of gut hormones seems to happen before 
meaningful BMI fall22 and days after surgery27. Comparing between restrictive and malabsortive 
surgeries, improvement of incretins after food stimulation tends to happen mainly and faster with 
surgeries with malabsortive features, which are also associated with better remission 
rates3,15,26,27.Even though increase of post-prandial GLP-1 tends to be link to remission, in a 2 years 
study, GLP-1 levels increased mainly in “no-remission” patients. This was probably due to 
pancreatic β-cell resistance to GLP-1 action28. GIP levels decreased with surgeries associated with 
high remission rates, BPD27 and RYGB2, or increased primarily with SG, rather than RYGB25. This can 
be probably explained by the intestinal manipulation inherent to malabsortive surgeries, which can 
reduce the production of this hormone, or by the increase efficiency of GIP, which tends to be 
decreased with DMT2.  
Despite the fact that SG is a restrictive procedure, is also associated with increase of 
incretins3,25, which is counterintuitive when others restrictive surgeries are evaluated11. This effect 
seems to happen due to an acceleration of food transit11,13,26, that causes exaggerated GLP-1 
release11 but the results are inconsisting11.  Still, SG tends to be less effective than RYGB in inducing 
DMT2 remission25. In the Lee et al. study, excepted for PYY 90 minutes after food stimulation, both 
GBy and SG produced the same effect on incretin levels, but factors associated with worst 
outcomes, such as insulin resistance, levels of resistin and abdominal fat, were linked mainly to 
SG25.  
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Other theories are emerging such as adiponectin rise, an anti-inflammatory hormone24,28, 
modification of small intestine microbiota, increase of bile acid concentration and diminished pro-
inflammatory state2,15,16,24. Changes on lifestyle, particularly, alterations on the type of food 
ingested, prioritizing healthier choices, have been reported after SG and RYGB. The reasons seem 
to be the increase of anorexigenic gut hormones, revulsion symptoms that can be triggered when 
ingesting certain types of foods and/or reduced stimulation of reward areas, normally activated 
with food intake11. 
Predictors of remission 
It has been established three models to predict remission of DMT2  after metabolic surgery: 
DiaRem, ABCD and Individualized metabolic surgery, IMS score48. The first was presented by Still et 
al. based on a retrospective study with 690 patients, all submitted to RYGB, and followed during 5 
years52. It scores from 0 to 22 and the probability of remission is presented in intervals52. ABCD 
score was first proposed by Lee et al. after identifying 4 variables as independent DMT2 remission 
factors in a study with 63 patients, submitted to either RYGB or Sleeve Billroth II GBy53. The IMS 
score was constructed based on a retrospective study with 659 obese patients undergoing either 
RYGB or SG and followed for minimum 5 years. Opposite to the other two scores, the aim of this 
score is to guide the physician choice between RYGB and SG, depending on severity of DMT2 and 
safety54,55. All scores and each variables are presented in table VI. 
Analyzing the variables included in the three remission scores, IMS and ABCD scores have 
“duration of DMT2” in common. This is a probable remission factor based on the principle that, in 
the early stages of the disease, obesity-induced insulin resistance has caused reversible β-cell 
dysfunction, but most of the insulin secretion is still normal9,45,56. If surgery is performed in this 
moment, changes in the insulin sensitivity induce stabilization of β-cell function, without bigger 
changes on glucose levels57. The rate of T2DM remission with bariatric surgery is been proven to be 
inversely related to the years of diabetes progression9,26,30,32,55,56,58. Advance-DiaRem, a score 
system based on DiaRem with addition of two variables, “duration of diabetes” and “number of 
ODA”, has showed to be more accurate than DiaRem in predicting which patient will enter 
remission 1 year after bariatric surgery59.  
Insulin use was considered a bad prognosis factor by various studies, either at short or long-
term 9,26,33,60,50,61. Parikh et al. observed that only 20% of insulin users entered remission during the 
first six months after bariatric surgery, compared to 80% of patients that didn’t use insulin 
preoperative62. Use and number of antidiabetic agents (oral/injectable), excepted for metformin, 
are predictors of bad outcome9,60,32,58,61. This is probably true, because the increase need of 
hypoglycemic agents represents a decrease of β-cell reservoir32. 
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Anthropometric parameters weren’t consistently associated to bariatric surgery outcome. 
Higher BMI at baseline was considered a predictor of good outcome in some studies30,36,48,60,58 and 
others didn’t acknowledge it56,40. In the Yan et al. study, 30 patients had BMI<24, meaning that this 
study can have different conclusions when compared to patients with BMI>3558. In a 3 years study, 
40% of the participants had BMI 30-35 kg/m2 and 60% BMI>35 kg/m2 and the authors showed that, 
independently of the obesity class, the patients had the same results38. Weight variation, in some 
studies, wasn’t associated with remission 37,42,56,63,40,50 or relapse37,43. On the contrary, WL after 
surgery was define as predictor of 1-year and long term remission in other studies33,42,55. Even 
though many studies acknowledged reduction of abdominal perimeter as a factor with bigger 
impact on remission, compared to the other anthropometric parameters, only one study proved 
the association of decrease abdominal fat and glucose control2. Upper body fat, emphasizing in the 
visceral fat, apparentely plays a big role on DMT2 evalution11,15. Visceral fat is known to be 
metabolically more active than subcutaneous fat, producing adipose-specific cytokines and pro-
inflammatory cytokines1.  
High preoperative HbA1c levels was define as predictor of bad outcome9,32,50,60 and is 
included in the IMS and ABDC score.  Good baseline glycemic control, define by diminished levels 
of FG, HbA1c or no use of insulin pre-surgery, was acknowledged as predictor of good outcome48,42 
and the SOS study highlighted baseline glucose concentration, presence/absence of IG and HOMA-
IR as factors linked to remission56. A rapid decrease of HbA1c after surgery was also define as 
predictor of remission at 1 year61. 
Baseline C-Peptide is only present at ABCD score as a variable associated with remission. 
Cheng et al. acknowledged fasting C-Peptide levels as the most important predictor of remission, 
because it reflects the reservoir of insulin in DMT2 patients48,58. Therefore, low levels are linked to 
worse control of glycemic status post-operative48,53. A meta-analysis conducted by Yan et al. 
affirmed the same, but had a small selection of articles and the percentage of insulin users and 
years of follow-up were very wide between studies, which could alter its conclusions64. In a study 
with inclusion criteria “BMI 30-35 kg/m2”, higher stimulated C-Peptide was defined as a remission 
factor at 24 months after surgery7. C-Peptide wasn’t measure in many studies, so its validation as a 
remission factor was limited. 
Patients with older age have less probability of entering remission9,60, contrarily to the 
younger individuals32,42,48,61. Though, some studies didn’t recognize “age” as a prognosis 
factor37,40,65. Gender was also not a variable consistent, with studies acknowledging male sex as a 
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good remission factor9, one study female sex, but only during the first year of follow-up60 and other 
didn’t even recognize gender as a remission factor at any point of follow-up40.  
Others likely to be remission factors not contemplated in any of the three scores, as for 
TG37, type of surgery51 or variation of GLP-126 require more studies, because, depending on the 
characteristics available/analyze in each study, the variables associated with outcome change and 
some variables aren’t recognize, because they’re not analyzed.  
Reviewing the efficacy of score systems, ABCD was considered superior to DiaRem and IMS 
scores in comparing study48,20. One problem with the DiaRem score is it applicability, because the 
participants of the original trial had mean BMI of 48 kg/m2 and were submitted only to GBy 
procedures. Not inclusion of duration of diabetes in the score also reduces its accuracy, based on 
the improvement of results with Advance-DiaRem.  The IMS score lacks on exploring other type pf 
surgeries and the original conclusions could be altered if the number of participants submitted to 
the two types of surgeries analyzed was equal (in the original study, 78% in the RYGB group and 
22% in the SG). The ABCD Score, even though it’s aknowledged as the score with better efficiency, 
only includes results after gastric bypass surggeries and, compared to the other two scores, had a 
very small population size (63 patients) and lower follow-up period (3 years). Inclusion of BMI and 
not hypoglycemic agents (injectable/oral) can question its efficacy, based on the results presented 
in various studies.   
Outcome 
Bariatric surgery can be divided into three types of procedures: restrictive, malabsorptive 
and a combination of the two. In surgeries with restrictive features, the stomach size is reduced, 
without any alteration to the intestinal architecture4. Three examples of restrictive procedures are 
GCP, LAGB and SG3. In LAGB, a small adjustable bandage is placed around the proximal portion of 
the stomach in order to produce a reduction of its size, leaving approximately 30 mL volume in 
total11. During the SG procedure a gastric sleeve tube is formed by resecting from beyond the gastric 
incisura until the angle of His, reducing the volume of the stomach by 75-80% 3,4,22,26.  
Malabsorptive procedures aim is to cause alterations on the absorption of nutrients by 
creating an intestinal bypass4. BPD, an example of these procedure, is based on the creation of a 
horizontal gastrectomy and anastomosis between the remain stomach and the distal part of the 
small intestine, excluding the duodenum, jejunum and part of the ileum23.  
RYGB is a mix procedure, combining restrictive features and malabsorptive. 3,22,26. This 
surgery is based on the creation of a small gastric pouch, approximately of 30 mL volume, 
anastomosed to the jejunum, creating a bypass pathway. 3,22,11 
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When comparing the outcome of the different types of bariatric surgery, is useful to 
separate the restrictive from the malabsortive surgeries. In one hand, the first ones are less capable 
of achieving long-term glucose control and improvement of metabolic comorbidities, but show less 
short and long terms complications, when related to malabsortive techniques4,14,63,66. 
In a meta-analysis comparing RYGB to conservative treatment during 12-60 months, 
bariatric surgery proved to be more effective in inducing DMT2 remission and changes on 
anthropometric parameters than to conservative treatment in obese patients at short and mild-
term follow-up. 16 In the studies analyzed in this review with inclusion criteria BMI≥35 kg/m2, 
complete DMT2 remission rates with bariatric surgery vary from 5-100% and with conservative 
measures from 0-14.4%. The range of remission rates was very wide because the studies had 
different follow-up time, number and selection of participants, baseline characteristics 
randomization, type of surgeries and conservative interventions and complete remission definition 
(tables 4 and 5). Bariatric surgery outperformed conservative measures in many parameters 
analyzed: anthropometric features, such as abdominal fat, TBF and BMI, HbA1c and FG 2,36-39. The 
number of patients using insulin/hypoglycemic agents decreased also in almost every surgical 
groups, 16,37-39 with either stabilization or increase2,37,39 in the respective comparative medical 
group. One important aspect is the probably of relapse, which happened in a few surgical 
groups2,9,37,38,42,43. In a 3 years study after RYGB 60% of patients achieved partial remission at 1 year, 
but this percentage reduced to 45% in year 2 and 40% in year 338. Even though some patients tend 
to relapse after surgery, an aspect that a few studies have highlighted is that these patients 
maintain improvement on glucose levels at short/long term, when compared to baseline, but not 
sufficient to meet the remission criteria established9,37,57. In the SOS bariatric surgery was proven 
to be superior to conservative treatment in preventing the development of DMT2 in patients with 
moderate obesity and IGT or normal glucose levels pre-surgery56. This shows that, beyond inducing 
remission, bariatric surgery improves glycemic status in almost every patient, which by itself helps 
to prevent complications associated to DM67. So, probably, instead of focusing in remission rates, 
the success of bariatric surgery should be based on the grade of glucose decrease. 
A relevant criterion for selection of diabetes treatment is the ability to reduce the incidence 
and severity of complications. In a study comparing RYGB to medical treatment, the risk of 
developing organ-damage associated with DM was inferior with RYGB, mainly microvascular 
complications. The incidence of total macrovascular complications was inferior in the RYGB group, 
though incidence of cerebrovascular and peripheral diseases was superior in this group9. In the 
same study, comparing patients that entered DMT2 remission and no-remission, the “remission” 
patients had an incidence of microvascular and macrovascular inferior to the “no-remission” group 
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by 57% and 24%, respectively9. In other study, microvascular complications developed mainly in 
the medical group compared to BPD/RYGB during a 5 years follow-up37 (table VII). Even though the 
number of new complications after Bariatric surgery tends to decrease, already established diabetic 
retinopathy doesn’t seems to reduce or aggravate43,67,68. 
Metabolic control38,39, improvement of lipid profile16,37 and reduction of cardiovascular risk 
37 all seem to improve more after bariatric surgery than conservative measures. Metabolic control 
(table VIII) was achieved by 13%, 68% and 100% of the patients in the MT, RYGB and BPD group, 
respectively, at 5 years in Mingrone et al study.37 In a RCT with 43 patients, the surgical group also 
had better control over metabolic factors, including decrease of SBP and HbA1c and tendency to 
increase HDL levels 36,40. The 10-year risk of fatal/nonfatal coronary heart disease, using United 
Kingdom Prospective Diabetes Study risk equation, showed big reductions after bariatric surgery 
compared to conservative measures17,36,69. Lipid profile doesn’t change uniformly, with studies 
reporting improvement only on HDL2, others on HDL and TG 36,43 and LDL, total cholesterol 16.  
According to IDF, AMBS and ADA guidelines, patients obese class I can be candidates for 
bariatric surgery, but only after failure of conservative measures4,45,46. Remission rate after surgery 
in these patients’ floats between 0-88% depending on DMT2 remission definition, population 
characteristics, follow-up time, BMI interval established and type of interventions7,25,57,62,63,70,71. 
Meta-analysis conducted in this topic show similar remission rates72,65. Other parameters were also 
improved after surgeries such as FG, HbA1c, need for hypoglycemic agents and HOMA-IR62, 65,71. 
Two studies disagree with this conclusion57,70. One study comparing open duodenal-jejunal 
exclusion surgery to ILI acknowledged only that surgery was superior to medical treatment on 
inducing HbA1c decrease. On the other parameters analyzed, optimization of ILI was able to achieve 
the same results surgery70. This study had as inclusion criteria baseline C-Peptide >1 ng/mL70. Other 
study, now comparing GB and metformin, had the same results and specific inclusion criteria: 
patients should have either impaired glucose tolerance or DMT2 diagnose <1 year57. These studies 
had small follow-up time (24 weeks 70and 2 years 57, small populations (24 and 88) and the type of 
surgeries studied are not the most used, so, even though apparently patients with modest DMT2 
don’t benefit from bariatric surgery, more studies must be performed in order to have conclusions 
to apply on general population. Analyzing groups of patients with BMI above or inferior to cut-offs 
established by IDF, submitted to the same type of bariatric surgery, improvement of glucose levels 
is seen in both groups and equal rates of complications, though remission rates and weight loss 
tend to be superior when BMI>35/30 kg/m2 49,73. This concludes that surgery’s a valid and safe 
option compared to conservative measures for patients with BMI under 35 and DMT2. More 
 20 
 
research in this population must be done, because there is a lack of studies about this subject and, 
those that exist, have small populations and short follow-up time. 
Anastomotic leakage and need for reconstruction, stenosis, gastroesophageal reflux 
disease, GERD, (if pre-surgery GERD exists, GB can deteriorate the condition), hernias, 
hemorrhages, ulcers, need for cholecystectomy, for example, are complications that health 
professionals should be alert postoperative16,23,65,72-74. Other complications are decrease of lean 
mass, especially reported after RYGB, with decreases that can go up to 10% from baseline, 36,38,40 
and decrease of bone mass23,38. In surgeries with malabsortive features, micronutrients deficiency 
such as vitamins, calcium, iron and folate are frequently and, even though protocols exist to prevent 
this kind of deficits, they are still important problems after surgery (table VII). The dumping 
syndrome, characterized by nauseas, vomiting or hypoglycemic symptoms, is associated with 
accelerated gastric emptying or quick exposure of nutrients to the small intestine that occurs mainly 
after RYGB (can occur in up to 40% depending on the series), but also with restrictive procedures74. 
Quality of life parameters, such as general health, physical function, emotional well-being and 
energy, improved mainly from baseline with bariatric surgery42,71. 
Mortality rates of bariatric surgery are very low nowadays, ranging from 0-0.5%21,45,72, 
similar to a cholecystectomy or hysteroscopy4, due to introduction of laparoscopy and more 
experienced surgeons21,45. Major complications, such as cardiopulmonary events or 
thromboembolic disease, are reported in a frequency of 2-6%, but this events are known to be the 
cause of 70% of the deaths after surgery21,45,50. 
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KEY LEARNING POINTS 
 
Gut hormones after bariatric surgery 
 Weight loss and food restriction aren’t the only factors linking bariatric surgery to DMT2 
remission11,24. 
 Mechanisms weight loss-independent, such as decrease of total/acyl ghrelin24,26, increase 
of incretins 3,15,26,27, intestinal bypass11,22,24,50 and rise of adiponectin24,28, are all variables 
altered after bariatric surgery and possibly related with T2DM remission. 
Guidelines 
 Patients with BMI≥40 kg/m2 should be offer bariatric surgery, regardless of glycemic control 
or number of hypoglycemic agents45. 
 Bariatric surgery can be recommended in patients with BMI 35-39.9 when conservative 
measures fails and can be suggested if good glucose control is achieved. 
 In individuals with BMI between 30-35 kg/m2 surgery can be suggested when optimize 
conservative measures are not effective on glucose control. 
 All cut-offs must be down 2.5kg/m2 if apply to Asian patients, because patients of this 
nationality are exposed to more DMT2 risk with lower BMI 48. 
Outcome 
 Bariatric surgery outperforms conservative measures on improvement of anthropometric 
parameters (weight loss, reduction of waist circumference and body fat) 2,37-39 and glucose 
control (HbA1c, FG, insulin resistance, reduction of hypoglycemic agents)16,37-39. 
 Bariatric surgery is associated with better metabolic control38,39, lipid profile16,37, reduction 
of cardiovascular risk37 and prevention of organ-damage9,37. 
 Micronutrient deficiencies, anastomic leakage and need for reconstruction, stenosis, 
gastroesophageal reflux disease and dumping syndrome are probable complications after 
bariatric surgery16,23,65,72,74. 
 Mortality rate associated with surgery is very low, 0-0.5%, due to introduction of 
laparoscopic and train surgeons 19,72. 
Predictors of remission 
 Duration of T2DM9,56, use of hypoglycemic agents pre-surgery and, possibly C-Peptide 
levels, are variables associated with surgery outcome. 
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 BMI or weight loss are not consistently linked to surgery outcome, so the actual use of BMI 
as criteria for inclusion/exclusion of patients for bariatric surgery is not appropriate 30,48,60,58. 
 The IMS, ABCD and DiaRem scores fail in including variables inconsistently associated with 
surgery outcome48,20. 
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CONCLUSION 
 
This review acknowledges the use of bariatric surgery as a treatment option for obese 
patients and diabetics type 2, with the aim of better control or resolution of DM.  
Bariatric surgery outperformed conservative measures in many points associated with 
improvement of weight and its comorbidities. DMT2 patients and obese class I apparently have 
benefits in doing bariatric surgery opposite to lifestyle interventions, but the current studies in this 
field have small populations and follow-up periods. So, for now, the decision to include these 
patients for surgery treatment must be individualize, balancing the pros and cons. 
The existing theories that explore the main mechanism associating improvement of glucose 
control and bariatric surgery show some evidence, but doesn’t seem to be just one pathway, but a 
combination of factors. Understanding the mechanisms involved is a positive step towards new 
lines of DMT2 treatment. 
Duration of DMT2 and use of hypoglycemic agents pre-surgery were factors associated with 
outcome in many studies, opposite to BMI, with inconsistent results. In the future, creation of an 
algorithm with variables proven to influence surgery prognosis would be a relevant tool for medical 
teams in approaching DMT2 treatment.  
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COMPLEMENTARY SECTION 
 
Table I- Criteria for DM diagnosis according to International Diabetes Federation 
 
Criteria for DM diagnosis based on International Diabetes Federation 
Fasting Plasma glucose (FPG) ≥126 mg/dL (≥7.0 mmol/L) 
Oral glucose tolerance test (OGTT) at 2 hours ≥200 mg/dL (11.1 mmol/L) 
Random plasma glucose in symptomatic patient ≥200 mg/dL (11.1 mmol/L) 
HbA1c≥6.5% (48 mmol/mol) 
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Figure 1- Articles selection methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial selection: 
N=413 articles 
Inclusion criteria: 
Articles in Portuguese or English; 
From 01/2009 to 01/2019; 
Reviews; meta-analyzes and clinical trials; 
 
 
 
 
Additional articles identified from 
reference list search 
N= 29 
 
 
Number of articles= 38 
(plus 7 articles/guidelines 
from various DMT2 
institutions and ADA website) 
Final articles selection  
N=74 
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Table II - Articles and correspondingly follow-up, number of participants, type of interventions and changes of 
baseline characteristics (HbA1c and BMI) 
 
Reference N Type of interventions Follow-
up time 
(years: 
y; 
months: 
m) 
Mean Io 
BMI 
(kg/m2) 
Mean 
Final BMI 
(kg/m2) 
 
Mean Io 
HbA1c, 
%; FG 
(mg/dl) 
Mean 
Final 
HbA1c, 
%; FG 
(mg/dl) 
Panunzi et 
al.30 
727 Surgical Group: RYGB, 
77, BPD, 20, GB,91, 
and VBG, 227 (415 in 
total) 
 
Medical treatment 
group: diet and 
exercise (312 patient) 
2y Surgical 
group: 
42.0±5.0 
Medical 
group: 
40.1±4.9 
 
Surgical 
group: 
32.4±5.0 
Medical 
group: 
39.0±4.9 
Surgical 
group: 
8.3±1.5 
Medical 
group: 
8.0±1.4 
Surgical 
group: 
5.8±1.0 
Medical 
group: 
7.2±1.0 
Xiang et al.57 88 Surgical Group: GB 
Medical Group: 
metformin 
Randomized 1:1 
2y  
Surgical 
group: 
35.7±2.9 
Medical 
group: 
35±29 
 
Surgical 
group: 
35.7±2.9 
Medical 
group: 
34.8±2.8 
 
mmol/m
ol 
Surgical 
group: 
41.2±4.6 
Medical 
group: 
40.1±4.5 
 
 
Surgical 
group: 
41.5±4.5 
Medical 
group: 
40.8±4.6 
Kashyap et 
al.2 
60 Surgical Group:  
RYGB or SG 
 
Medical Group:  
Intensive Medical 
Treatment 
Randomized 1:1:1 
2y  
Surgical 
group: 
RYGB: 
36.1±2.6 
SG:       
36.4± 3.2 
Medical 
group: 
35.8±3.0 
 
 
Surgical 
group: 
RYGB: 
27.4±2.9 
SG: 
28.2±2.9 
Medical 
group: 
35.6±3.1 
 
Surgical 
group: 
RYGB: 
9.8±1.35 
SG:      
9.7± 1.95 
Medical 
group: 
9.5±1.73 
 
Surgical 
group: 
RYGB: 
6.7±1.23 
SG: 
7.1±0.84 
Medical 
group: 
8.4±3.3 
Parikh et 
al.62 
57 Surgical group:  
RYGB, SG and GB: 
29 patients; 
ILI (diet, exercise and 
ODA): 28 patients 
6m  
Surgical 
group: 
32.8 
ILI: 32.4 
(mean) 
 
Surgical 
group: 
25.9 
 ILI: 31.4 
(mean) 
 
Surgical 
group: 
7.4 
ILI:7.7 
(mean) 
 
Surgical 
group: 
6.2 
ILI:7.8 
(mean) 
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Schauer et 
al.42 
 
150 Surgical group:  
RYGB or SG 
ILI 
Randomized 1:1:1 
3y  
Surgical 
group: 
RYGB: 
37.0±3.3 
SG:  
36.2±3.9 
Medical 
group: 
36.8±3.0 
(not 
reported) 
% of WL: 
Surgical 
group: 
RYGB:            
-24.5±9.1 
SG:                
-21.1±8.9 
Medical 
group:           
-4.2±8.3 
 
Surgical 
group: 
RYGB: 
9.3±1.4 
SG:9.5±1
.7 
Medical 
group: 
9.0±1.4 
 
Surgical 
group 
RYGB: 
7.3±1.5 
SG: 
7.4±1.6 
Medical 
group: 
8.5±2.2 
 
Cummings 
et al.40 
43 Surgical group: RYGB 
ILI: ≥ 45 minutes of 
aerobic exercises 5 
days/week, diet 
focused on glucose 
levels improvement 
and optimized 
medical therapy 
1y Surgical 
group: 
38.3 
ILI group: 
37.1 
Mean 
Weight 
(kg) 
Surgical 
group: 
108.8 
ILI group: 
112.8 
BMI not 
reported 
Mean 
Weight 
(kg) 
Surgical 
group:    
80.7 
ILI group: 
105.6 
 
 
Surgical 
group: 
7.7±1.0 
 
ILI group: 
7.3±0.9 
 
 
Surgical 
group: 
6.4±1.6 
 
ILI group: 
6.9±1.3 
Carlsson et 
al.56 
3456 Surgical group:  
1685 participants 
total 
311 GB; 207 GBy; 
1140 VBG; 
Medical group:  
1771 participants 
15y Surgical 
group: 
42.4±4.5 
Medical 
group: 
40.2±4.7 
 
 
HbA1c 
levels 
not 
reported 
Blood 
glucose 
(mg/dL) 
Surgical 
group: 
80.3    
±10.8 
Medical 
group: 
79.0± 
11.0 
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Mingrone et 
al.37 
60 Surgical group:  
RYGB or BPD 
Medical treatment 
Randomized in 1:1:1 
5y  
Surgical 
group: 
BPD: 44.7 
RYGB:44.0 
Medical 
group: 
45.4 
 
 
Surgical 
group: 
BPD: 30.3 
RYGB:31.3 
Medical 
group:42.1 
 
Surgical 
group: 
BPD: 8.9 
RYGB: 
8.7 
Medical 
group: 
8.5 
 
Surgical 
group: 
BPD: 6.4 
RYGB: 
6.7 
Medical 
group: 
6.9 
Courcoulas 
et al.38 
61 Surgical group: 
RYGB: 21 patients 
LAGB: 20 patients 
ILI: 20 patients 
3y  
Surgical 
group: 
RYGB: 
35.67 
LAGB: 
35.58 
ILI: 35.75 
 
Surgical 
group: 
RYGB: 
26.97 
LAGB: 
30.39 
ILI: 34.0 
 
Surgical 
group: 
RYGB:8.5
6 
LAGB:7.8
7 
ILI: 7.03 
 
 
Surgical 
group: 
RYGB:7.1
4 
LAGB:7.0
7 
ILI: 7.24 
Bhandari et 
al.39 
90  
 
RYGB: 30 patients 
Medical group: 
GLP-1 analog: 30 
patients 
SGLT2 inhibitor: 30 
patients 
 
12m  
RYGB: 
34.1±0.65 
Medical 
group: 
GLP-1 
analog: 
32.65±1.1 
SGLT2 
inhibitor: 
31.4±0.75 
 
 
RYGB: 
27.4±1.3 
Medical 
group: 
GLP-1 
analog: 
30.88±1.1 
SGLT2 
inhibitor: 
31.3±0.7 
 
 
RYGB: 
8.1±0.53 
Medical 
group: 
GLP-1 
analog: 
7.6±0.5 
SGLT2 
inhibitor: 
7.8±0.63 
 
RYGB: 
5.7±0.6 
Medical 
group: 
GLP-1 
analog: 
7.2±0.3 
SGLT2 
inhibitor: 
7.8±0 
Simonson et 
al.36 
38  
RYGB: 19 patients 
ILI, including 
hypoglycemic agents: 
19 patients 
3y  
RYGB: 36.0 
ILI: 36.5 
 (mean) 
 
RYGB: 27.3  
ILI: 34.7 
 (mean) 
 
RYGB:8.2
4  
 ILI: 8.78 
 (mean) 
 
RYGB:6.4
5 
ILI: 8.39 
 (mean) 
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Table IIII- Criteria for partial, complete and long-term remission established by ADA 
 
 Definition according to ADA Consensus31 
Partial Remission HbA1<6.5%, FG 100-125 mg/dL for at least one year without 
hyoglycemic medication 
Complete Remission HbA1c<5.6% and FG<100 mg/dL for at least one year without 
hyoglycemic medication 
Long-term remission Complete remission for at least 5 years 
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Table IV- Remission definition, rate of remission and relapse according to articles included in this review 
 
References 
Definition of DMT2 
remission 
% of patients in remission Relapse 
Panunzi      
et al.30 
FG<5,6 mmol/L without 
ODA or insulin 
(at 2 years)                         
Surgical group: 63.7% 
Medical group: 14.4% 
 
Not documented 
Kashyap      
et al.2 
End-point: HbA1c≤6.0% 
Surgical groups:                    
RYGB: 33.3%; SG: 11% 
Medical Treatment: 6% 
15% from year 1 to 
year 2 in the SG group 
Cummings 
et al.40 
HbA1c<6% with no 
antidiabetic mediation at 
least for a year 
Surgical group: 60% 
ILI group: 5.9% 
Not documented 
Schauer      
et al.41-43 
 
HbA1c<6.5% without 
hypoglycemic treatment 
Surgical group (3,5 years): 
RYGB: 46%; 31% 
SG: 22%; 23.4% 
Medical group (3,5 years):            
0%; 0% 
Relapse at 3 years 
(HbA1c<6% at year 1 
but not at 3 years): 
Surgical group: 
 
RYGB: 24% 
SG: 50% 
Medical group: 80%. 
Mingrone     
et al.37 
Complete remission: 
 FPG≤5.6 mmol/L plus 
HbA1≤6.5% without 
medication for 1 year; 
 
-Partial remission: FPG 5.6-
6.9 mmol/L plus HbA1≤6.5% 
without medication for 1 
year 
 
1. Complete remission: 
Surgical group: 
BPD: 0% 
RYGB: 0% 
Medical group: 0% 
 
2. Partial remission: 
Surgical group: 
BPD: 63% 
RYGB: 37% 
Medical group: 0% 
 
Relapse:           
hyperglycemia at 5 
years after achieving 
partial remission at 2 
years: 
Surgical group: 
 
BPD: 37% 
RYGB: 53% 
Medical group: 0% 
Courcoulas 
et al.38 
Complete remission:  
HbA1c<5.7% plus FPG≤100 
mg/dL and no medication ≥1 
year; 
 
Partial remission:        
HbA1c<6.5% plus FPG≤125 
mg/dL and no medication ≥1 
year 
 
1.Complete remission: 
RYGB: 15% 
LAGB: 5% 
ILI: 0% 
 
2. Partial remission: 
RYGB: 25% 
LAGB: 24% 
ILI: 0% 
 
Relapse:   20% in the 
RYGB group from year 
1 to 3 
Bhandari    
et al.39 
Remission: HbA1c<6.5% 
RYGB: 100%; 
 
Medical group: 
GLP-1 analog: 0%; 
SGLT-2 inhibitor: 0%; 
Not documented 
 31 
 
Madsen      
et al.9 
Complete  remission: 
HbA1c<6.0% with only 
metformin as hypoglycemic 
agent or HbA1c<6.5% 
without any medication 
RYGB: 
At 5 years: ≥70%; 
Relapse:                    
HbA1c>6.5% or a 
prescription for a 
hypoglycemic agent 
after initial 
discontinuation 
between year 1 and 
year 5; 
27% from the RYGB 
 
Simonson    
et al.36 
Remission: 
HbA1c<6.5% and FPF<126 
mg/dL 
 
RYGB: 42.1% 
(without hypoglycemic 
medication: 36.8%) 
ILI: 0% 
Relapse                              
(from year 1 to 3):         
16% (3/19) in the ILI 
and 21% in the RYGB  
(4/19); 
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Table V- Algorithm for Bariatric surgery in patients with DMT2 according to DSS-II 
 
Patients with DMT2 
Obese 
BMI≥30 kg/m2                                                               
(or ≥27.5 if Asian Patient) 
Non obese 
BMI<30 kg/m2                                                           
(or <27.5 if Asian Patient) 
 Non-surgical treatment 
 
Obese class I 
BMI 30-34.9 kg/m2                                                   
(or 27.5-32.4 if Asian Patient) 
 
 First Line: Optimal lifestyle and 
medical interventions (including 
injectable hypoglycemic agents and 
insulin) 
 
 Second line if optimal glucose control 
is not achieved with conservative 
measures: suggest bariatric surgery 
 
 
Obese class II 
BMI 35-39.9 kg/m2                                                   
(or 32.5-37.4 if Asian patient) 
 First Line: Optimal lifestyle and 
medical interventions 
 
 Second line if optimal glucose control 
is not achieved with conservative 
measures: recommend bariatric 
surgery 
 
 Alternative if optimal glucose control 
is achieved with conservative 
measures:  Suggest bariatric surgery 
 
 
Obese class III  
BMI≥40 kg/m2                                                             
(or 37.5 if Asian Patient) 
 Recommend bariatric surgery 
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Table VI- Remission scores (IMS, ABCD and DiaRem score) 
 
 Score 
 
 
 
Variables 
IMS Score55 ABCD Score53 DiaRem Score 52 
Duration of DMT2 Duration of DMT2 Baseline HbA1c 
Number of 
hypoglycemic agents 
pre-surgery 
C-Peptide Levels at 
baseline 
Type of 
hypoglycemic 
medication 
Glycemic control, 
define as HbA1c<7% 
Age Age 
Insulin Use BMI at baseline Insulin Use 
 
 
 
Score and Probability 
of Remission, (%) 
 
Mild DMT2:               
≤25 
10-9 0-2: 88-99% 
8-7 3-7: 64-88% 
Moderate DMT2:      
26-95 
6-5 3-7: 64-88% 
4-3 8-12: 23-49% 
Severe DMT2             
>95 
2-0 13-17: 11-33% 
18-22: 2-16% 
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Table VII- Article, corresponding follow-up period, type of interventions and complications associated with 
each intervention 
 
                  Characteristics of 
study 
 
Reference 
 
Follow-up 
(years ,y; 
months, 
m) 
 
Medical Treatment ± 
Lifestyle Interventions 
[number of patients] 
 
Bariatric surgery 
(the type of surgeries 
included in the study) 
[number of patients] 
Mingrone et al.37 5y Major complication:         
[1] fatal acute myocardial 
infarction; 
Diabetes complications: 
Development of [1] 
retinopathy; [1] 
nephropathy; [2] 
neuropathy  
Minor complications: 
Persistent diarrhea 
associated with the use of 
metformin; 
 
No metabolic complication 
associated 
(RYGB and BPD) 
No major complication 
Early complications:         
[1] incisional hernia 
requiring surgery with 
BPD;  [1] intestinal 
obstruction with RYGB; 
Diabetes complications: 
Development of [1] 
nephropathy after RYGB; 
Minor complications:       
[2] hypoglycemia events 
with RYGB; 
Metabolic complications: 
BPD 
[5] Iron deficiency anemia; 
[3] Hypoalbuminemia;    
[3] Osteopenia;                 
[2] Renal calculus; 
RYGB 
[3] Iron deficiency anemia; 
[1] osteopenia;                         
[1] renal calculus. 
Yan et al.16  Major complications:      
[1] fatal acute myocardial 
infarction; 
 
Metabolic complications:  
reported 62.63% patients; 
[39] hypoglycemic events; 
[7] renal calculus;             
[6] anemia; 
More episodes of 
depression compared to 
the surgical group; 
 
(RYGB) 
Major complication:        
[1] jejunojejunosyomy 
leakage, that led to anoxic 
brain injury, lower 
extremity amputation and 
long-term disability; 
 
Minor and metabolic 
complications:            
reported in 80.4% patients 
[11] anemia;                    
[35] hypoglycemic events;   
[4] intestinal obstructions;  
[8) anastomotic ulcer; 
Casajoana et al.26 12m  
 
Major complications: 
(RYGB)                                
[1] hemoperitoneum;      
[2] gastrojejunal and 
ileoileal anastomotic 
hemorrhages;               
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(GCP)                                   
[1] hemoperitoneum; 
Early complications:       
(SG and RYGB)                   
[2] intra-abdominal 
collection;                       
(SG) [1] wound infection; 
(GCP) [2] vomiting and [1] 
gastroesophageal reflux. 
Xiang et al.57 2y (metformin) 
 
Minor gastrointestinal 
symptoms. 
(GB) 
Major complications:      
[2] band slippage with the 
implication of removal;    
[1] cholecystectomy due 
to acalculous cholecystitis. 
Cummings et al.18 1y (Intensive lifestyle 
intervention) 
No major complications 
[64] minor complications: 
[39] hypoglycemic events; 
[4] severe hypoglycemic 
events;                               
[7] musculoskeletal 
complaints. 
(RYGB) 
No major complications; 
[31] minor complications: 
[16] hypoglycemic events; 
[0] severe hypoglycemic 
events;                               
[2] musculoskeletal 
complains. 
Geloneze et al.70 24 weeks ILI 
No major complications; 
Minor complications:           
Hypoglycemic episodes in 
83% patients. 
(ODJS) 
No major complications; 
Minor complications:           
[2] wound infections;     
[10] Persisting nauseas 
during the first 2-4 weeks; 
[3] Hypoglycemic events;            
[6] Vomits. 
Carlsson et al.56 15y  
 
(GB; GBy; VBG) 
Major complications:           
[3] deaths within 90-days 
post-operative;              
[16] thromboembolism; 
[79] pulmonary 
complications; 
Minor complications: 
[53] vomits;                         
[35] wound infections; 
[18] hemorrhages;           
[23] anastomotic leakages, 
peritonitis or abscess. 
Schauer et al.43 5y (intensive lifestyle and 
medical intervention) 
Major complications:               
[1]  fatal myocardial 
infarction; 
Minor complications:       
[1] GI ulcer;                        
[3] Episodes of 
(SG and RYGB) 
Complications in the SG 
group:                                  
[1] Stroke;                             
[1] GI ulcer;                      
[13] Gastroesophageal 
reflux disease;                   
[4] Episodes of 
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dehydration;                       
[9] Gastroesophageal 
reflux disease;                    
[7] Anemia;                        
[39] Hypoglycemic events;  
[6] Renal calculus;            
[6] Nephropathy;               
[4] Neuropathy; 
[11]Depression. 
dehydration;                          
[1] Dumpling syndrome; 
[2] Retinopathy;                
[9] Nephropathy;               
[5] Renal calculus;           
[2] Foot ulcer;                   
[5] Neuropathy;               
[24] Anemia;                    
[40] Hypoglycemic events; 
[12] Depression;                     
[3] Wound infection; 
Complications in the RYGB 
group:                                   
[4] GI ulcer;                            
[5] Gastroesophageal 
reflux disease;                  
[2] Intra-abdominal 
bleeding;                              
[7] Episodes of 
dehydration;                      
[4] Dumpling syndrome; 
[1] Retinopathy;               
[11] Nephropathy;               
[6] Renal calculus;             
[2] Foot ulcer;                     
[1] Neuropathy;                 
[14] Anemia;                          
[32] Hypoglycemic events; 
[2] Severe hypoglycemic 
event;                                        
[1] Ketoacidosis. 
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Table VIII- Metabolic control criteria by IDF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolic Control by IDF (presence of ≥2 
criteria) 
Reduction of hypoglycemic medication 
± 
Reduction of baseline HbA1c ≥20% 
± 
Systolic Blood Pressure (SBP)<135 mmHg 
± 
Diastolic Blood Pressure (DBP)<85 mmHg 
± 
LDL<2.3 mmol/L 
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